Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 9:8:12.
doi: 10.1186/1748-717X-8-12.

Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras

Irene Karam  1 , Sarah Hamilton, Alan Nichol, Ryan Woods, Caroline Speers, Hagen Kennecke, Scott Tyldesley
Affiliations

Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras

Irene Karam et al. Radiat Oncol. .

Abstract

Purpose: To evaluate the survival of patients with human epidermal growth factor receptor 2 (HER2) positive and negative metastatic breast cancer irradiated for brain metastases before and after the availability of trastuzumab (T).

Materials and methods: Women diagnosed with brain metastasis from breast cancer in two eras between 2000 and 2007 (T-era, n = 441) and 1986 to 1992 (PreT-era, n = 307), treated with whole brain radiotherapy (RT) were identified. In the T-era, HER2 testing was part of routine clinical practice, and in the preT-era 128/307 (42%) cases had HER2 testing performed retrospectively on tissue microarrays. Overall survival (OS) was estimated using the Kaplan-Meier method and comparisons between eras used log-rank tests.

Results: In the preT- and T-era cohorts, the rate of HER2 positivity was 40% (176/441) and 26% (33/128) (p < 0.001). The median time from diagnosis to brain RT was longer in the preT-era (3.3 years versus 2.3 years, p < 0.001). Survival after brain RT was improved in the T-era compared to the preT-era (1-year OS 26% versus 12%, p < 0.001). The 1-year OS rate for HER2 negative patients was 20% in both eras (p = 0.97). Among HER2 positive patients, the 1-year OS in the preT-era was 5% compared to 40% in the T-era (p < 0.001).

Conclusions: Distinct from patients with HER2 negative disease in whom no difference in survival after brain RT was observed over time, patients with HER2 positive brain metastases experienced significantly improved survival subsequent to the availability of trastuzumab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival by era: HER2 negative patients.
Figure 2
Figure 2
Overall survival by era: HER2 positive patients.
Figure 3
Figure 3
Overall survival by era and RPA class: (A) RPA 1; (B) RPA 2; (C) RPA 3.
See this image and copyright information in PMC

References

    1. Leyland-Jones B. Human epidermal growth factor receptor 2–positive breast cancer and central nervous system metastases. J Clin Oncol. 2009;27:5278–5286. doi: 10.1200/JCO.2008.19.8481. - DOI - PubMed
    1. Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O’reilly SE, Olivotto IA. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–979. doi: 10.1002/cncr.22867. - DOI - PubMed
    1. Tsao MN, Lloyd NS, Wong RK, Rakovitch E, Chow E, Laperriere N. Supportive Care Guidelines Group of Cancer Care Ontario’s Program in Evidence-based Care. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2005;31:256–273. doi: 10.1016/j.ctrv.2005.04.007. - DOI - PubMed
    1. Tsao MN, Lloyd N, Wong R, Chow E, Rakovitch E, Laperriere N. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev. 2012;4:CD003869. - PMC - PubMed
    1. Spector NL, Blackwell KL. Understanding the mechanisms behind Trastuzumab therapy for human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol. 2009;27:5838–5847. doi: 10.1200/JCO.2009.22.1507. - DOI - PubMed

Publication types

MeSH terms